173 related articles for article (PubMed ID: 36793190)
1. Claudin18.2 expression and clinicopathological features in cytology effusion specimens from gastric adenocarcinoma: A comparative study with tissue specimens.
Dai J; Zheng H; Jin J; Cheng Y; Xu H
Cancer Cytopathol; 2023 Jun; 131(6):365-372. PubMed ID: 36793190
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Claudin 18.2 expression in primary tumors and lymph node metastases in Japanese patients with gastric adenocarcinoma.
Rohde C; Yamaguchi R; Mukhina S; Sahin U; Itoh K; Türeci Ö
Jpn J Clin Oncol; 2019 Sep; 49(9):870-876. PubMed ID: 31087075
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer.
Kubota Y; Kawazoe A; Mishima S; Nakamura Y; Kotani D; Kuboki Y; Bando H; Kojima T; Doi T; Yoshino T; Kuwata T; Shitara K
ESMO Open; 2023 Feb; 8(1):100762. PubMed ID: 36610262
[TBL] [Abstract][Full Text] [Related]
4. CLDN18.2 expression and its impact on prognosis and the immune microenvironment in gastric cancer.
Wang C; Wang Y; Chen J; Wang Y; Pang C; Liang C; Yuan L; Ma Y
BMC Gastroenterol; 2023 Aug; 23(1):283. PubMed ID: 37582713
[TBL] [Abstract][Full Text] [Related]
5. Clinical Implications of Claudin18.2 Expression in Patients With Gastric Cancer.
Baek JH; Park DJ; Kim GY; Cheon J; Kang BW; Cha HJ; Kim JG
Anticancer Res; 2019 Dec; 39(12):6973-6979. PubMed ID: 31810969
[TBL] [Abstract][Full Text] [Related]
6. FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma.
Sahin U; Türeci Ö; Manikhas G; Lordick F; Rusyn A; Vynnychenko I; Dudov A; Bazin I; Bondarenko I; Melichar B; Dhaene K; Wiechen K; Huber C; Maurus D; Arozullah A; Park JW; Schuler M; Al-Batran SE
Ann Oncol; 2021 May; 32(5):609-619. PubMed ID: 33610734
[TBL] [Abstract][Full Text] [Related]
7. Correlation of Claudin18.2 expression with clinicopathological characteristics and prognosis in gastric cancer.
Tao D; Guan B; Li Z; Jiao M; Zhou C; Li H
Pathol Res Pract; 2023 Aug; 248():154699. PubMed ID: 37487317
[TBL] [Abstract][Full Text] [Related]
8. Global Ring Study to Investigate the Comparability of Total Assay Performance of Commercial Claudin 18 Antibodies for Evaluation in Gastric Cancer.
Jasani B; Taniere P; Schildhaus HU; Blighe K; Parry S; Wilkinson D; Atkey N; Clare-Antony S; McCabe C; Quinn C; ; Dodson A
Lab Invest; 2024 Jan; 104(1):100284. PubMed ID: 37949357
[TBL] [Abstract][Full Text] [Related]
9. Zolbetuximab for Claudin18.2-positive gastric or gastroesophageal junction cancer.
Kubota Y; Shitara K
Ther Adv Med Oncol; 2024; 16():17588359231217967. PubMed ID: 38188462
[TBL] [Abstract][Full Text] [Related]
10. Expression of the potential therapeutic target claudin-18.2 is frequently decreased in gastric cancer: results from a large Caucasian cohort study.
Dottermusch M; Krüger S; Behrens HM; Halske C; Röcken C
Virchows Arch; 2019 Nov; 475(5):563-571. PubMed ID: 31332522
[TBL] [Abstract][Full Text] [Related]
11. Enrichment of CLDN18-ARHGAP fusion gene in gastric cancers in young adults.
Nakayama I; Shinozaki E; Sakata S; Yamamoto N; Fujisaki J; Muramatsu Y; Hirota T; Takeuchi K; Takahashi S; Yamaguchi K; Noda T
Cancer Sci; 2019 Apr; 110(4):1352-1363. PubMed ID: 30771244
[TBL] [Abstract][Full Text] [Related]
12. Analysis of the expression and genetic alteration of CLDN18 in gastric cancer.
Li J; Zhang Y; Hu D; Gong T; Xu R; Gao J
Aging (Albany NY); 2020 Jul; 12(14):14271-14284. PubMed ID: 32668412
[TBL] [Abstract][Full Text] [Related]
13. Claudin18.2-Specific Chimeric Antigen Receptor Engineered T Cells for the Treatment of Gastric Cancer.
Jiang H; Shi Z; Wang P; Wang C; Yang L; Du G; Zhang H; Shi B; Jia J; Li Q; Wang H; Li Z
J Natl Cancer Inst; 2019 Apr; 111(4):409-418. PubMed ID: 30203099
[TBL] [Abstract][Full Text] [Related]
14. Coupling CDH17 and CLDN18 markers for comprehensive membrane-targeted detection of human gastric cancer.
Matsusaka K; Ushiku T; Urabe M; Fukuyo M; Abe H; Ishikawa S; Seto Y; Aburatani H; Hamakubo T; Kaneda A; Fukayama M
Oncotarget; 2016 Sep; 7(39):64168-64181. PubMed ID: 27580354
[TBL] [Abstract][Full Text] [Related]
15. Colitis-associated colorectal adenocarcinomas frequently express claudin 18 isoform 2: implications for claudin 18.2 monoclonal antibody therapy.
Iwaya M; Hayashi H; Nakajima T; Matsuda K; Kinugawa Y; Tobe Y; Tateishi Y; Iwaya Y; Uehara T; Ota H
Histopathology; 2021 Aug; 79(2):227-237. PubMed ID: 33590909
[TBL] [Abstract][Full Text] [Related]
16. Claudin-18.2 testing and its impact in the therapeutic management of patients with gastric and gastroesophageal adenocarcinomas: A literature review with expert opinion.
Angerilli V; Ghelardi F; Nappo F; Grillo F; Parente P; Lonardi S; Luchini C; Pietrantonio F; Ugolini C; Vanoli A; Fassan M
Pathol Res Pract; 2024 Feb; 254():155145. PubMed ID: 38277741
[TBL] [Abstract][Full Text] [Related]
17. Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy.
Cao W; Xing H; Li Y; Tian W; Song Y; Jiang Z; Yu J
Biomark Res; 2022 May; 10(1):38. PubMed ID: 35642043
[TBL] [Abstract][Full Text] [Related]
18. Highly expressed Claudin18.2 as a potential therapeutic target in advanced gastric signet-ring cell carcinoma (SRCC).
Xu B; Liu F; Liu Q; Shi T; Wang Z; Wu N; Xu X; Li L; Fan X; Yu L; Liu B; Wei J
J Gastrointest Oncol; 2020 Dec; 11(6):1431-1439. PubMed ID: 33457012
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of claudin 18.2 expression in gastric adenocarcinoma.
Kayikcioglu E; Yüceer RO; Cetin B; Yüceer K; Karahan N
World J Gastrointest Oncol; 2023 Feb; 15(2):343-351. PubMed ID: 36908327
[TBL] [Abstract][Full Text] [Related]
20. Evidence to Date on the Therapeutic Potential of Zolbetuximab in Advanced Gastroesophageal Adenocarcinoma.
Rogers JE; Ajani J
Curr Oncol; 2024 Feb; 31(2):769-777. PubMed ID: 38392051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
